文献速递儿童内分泌与遗传代谢儿童心血管与肾脏

儿童期生长激素治疗与远期心血管疾病风险的关联

Association of Childhood Growth Hormone Treatment With Long-term Cardiovascular Morbidity.
PubMed 文献 · JAMA Pediatr · 2021-02-01

结果显示,rhGH治疗与总体心血管事件风险升高相关(校正HR 1.69,95%CI 1.30-2.19),女性风险更高,且与治疗时长和累积剂量相关,但绝对风险仍低。

要点

  • 儿童期rhGH治疗与总体心血管事件风险升高相关,校正HR 1.69(95%CI 1.30-2.19)。
  • 女性风险高于男性(HR 2.05 vs 1.55),且与治疗时长和累积剂量相关。
  • 严重心血管事件校正HR 2.27(95%CI 1.01-5.12),但绝对风险仍低,因果结论有限。

核心结论

  • 儿童期因GHD、SGA或ISS接受rhGH治疗与成年早期心血管事件风险升高相关,尤其是女性,但因果推断有限且绝对风险仍低。

研究设计与样本

  • 瑞典全国性 population-based 队列研究,纳入1985年1月1日至2010年12月31日儿童期接受rhGH治疗的患者,随访至2014年12月31日。

主要发现

  • 患者总体心血管事件校正HR为1.69(95%CI 1.30-2.19),女性HR为2.05(95%CI 1.31-3.20),男性HR为1.55(95%CI 1.12-2.13)。
  • 各亚组HR均升高:SGA 1.97(95%CI 1.28-3.04),GHD 1.66(95%CI 1.21-2.26),ISS 1.55(95%CI 1.01-2.37)。
  • 较长治疗时长(HR 2.08,95%CI 1.35-3.20)和总累积剂量(HR 2.05,95%CI 1.18-3.55)与总体心血管疾病风险升高相关。
  • 严重心血管疾病校正HR为2.27(95%CI 1.01-5.12)。

临床怎么用

  • 对儿童期接受rhGH治疗者,尤其女性及治疗时长较长或累积剂量较高者,应关注远期心血管风险。
  • 临床决策时需权衡rhGH治疗的获益与潜在心血管风险,但因果证据有限且绝对风险低。

局限性

  • 观察性设计限制因果推断,原文指出因果结论仍有限。
  • 绝对风险仍低,且随访至成年早期,长期风险需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Concerns about the cardiovascular safety of recombinant human growth hormone (rhGH) treatment in childhood have recently been raised; however, long-term studies are limited. OBJECTIVE: To investigate the long-term risk of overall and severe cardiovascular events in patients previously treated with rhGH in childhood and whether there is an association with treatment duration or dose. DESIGN, SETTING, AND PARTICIPANTS: This nationwide population-based cohort study included patients treated with rhGH during childhood from January 1, 1985, to December 31, 2010, in Sweden, with follow-up through December 31, 2014. Included patients were treated with rhGH owing to isolated growth hormone deficiency (GHD), small for gestational age (SGA), and idiopathic short stature (ISS). For each patient, 15 age-, sex-, and region-based matched control individuals were randomly selected from the general population as a comparison group. Data on cardiovascular outcomes and covariates including gestational age, birth weight, birth length, socioeconomic status, and height were obtained through linkage with several health care and population-based registers. Data were analyzed from January 1, 1985, to December 31, 2014. EXPOSURES: Treatment with rhGH during childhood and adolescence (aged 0-18 years). MAIN OUTCOMES AND MEASURES: The primary outcome was the first cardiovascular event recorded after the start of follow-up, and the secondary outcome was the first severe cardiovascular event. RESULTS: A total of 53 444 individuals (3408 patients and 50 036 controls; 67.7% men; mean [SD] age at study end, 25.1 [8.2] years) were followed up for as long as 25 years (median follow-up, 14.9 [range, 0-25] years; total, 795 125 person-years). Among 1809 recorded cardiovascular events, the crude incidence rates were 25.6 events per 10 000 person-years for patients and 22.6 events per 10 000 person-years for controls. The adjusted hazard ratio (HR) for all cardiovascular events was higher in patients compared with controls (HR, 1.69; 95% CI, 1.30-2.19), especially for women (HR, 2.05; 95% CI, 1.31-3.20) compared with men (HR, 1.55; 95% CI, 1.12-2.13). All subgroups had increased HRs (SGA, 1.97 [95% CI, 1.28-3.04]; GHD, 1.66 [95% CI, 1.21-2.26]; and ISS, 1.55 [95% CI, 1.01-2.37]). Longer duration of rhGH treatment (HR, 2.08; 95% CI, 1.35-3.20) and total cumulative dose (HR, 2.05; 95% CI, 1.18-3.55) were associated with higher risk for overall cardiovascular disease. The adjusted HR for severe cardiovascular disease was 2.27 (95% CI, 1.01-5.12). CONCLUSIONS AND RELEVANCE: In this cohort study, treatment with rhGH during childhood due to GHD, SGA, or ISS was associated with increased risks of cardiovascular events in early adulthood, particularly in women; however, conclusions of causality are still limited and the absolute risk remains low.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Tidblad A, Bottai M, Kieler H, et al. Association of Childhood Growth Hormone Treatment With Long-term Cardiovascular Morbidity. JAMA Pediatr. 2021. PMID: 33346824. doi:10.1001/jamapediatrics.2020.5199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。